Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period. These considerations are based both on the available medical literature and on our clinical experience following the use of these implants in this type of patient, the goal being to optimize the number of injections and the clinical outcome of this therapy. We also provide a general overview of the pathophysiology of DME, highlighting the inflammatory component as a rationale to use steroids in these patients.

Journal Section:
Research Article
Keywords:
Diabetic macular edema, Dexamethasone intravitreal implant, Inflammatory disease, Anti-vascular endothelial growth factor therapy
1.
Das A, McGuire PG, Rangasamy S: Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015; 122: 1375–1394.
[PubMed]
https://doi.org/10.1016/j.ophtha.2015.03.024
2.
Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904–1914.
[PubMed]
https://doi.org/10.1016/j.ophtha.2014.04.024
3.
Callanan DG, Loewenstein A, Patel SS, Massin P, Corcóstegui B, Li XY, et al: A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017; 255: 463–473.
[PubMed]
https://doi.org/10.1007/s00417-016-3472-1
4.
Panozzo G, Gusson E, Panozzo G, Dalla Mura G: Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment. Eur J Ophthalmol 2015; 25: 347–351.
[PubMed]
https://doi.org/10.5301/ejo.5000563
5.
Estrategia en diabetes del Sistema Nacional de Salud. Madrid, Ministerio de Sanidad, Servicios Sociales e Igualdad. Centro de publicaciones, 2012.
6.
Lorber D: Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014; 7: 169–183.
[PubMed]
https://doi.org/10.2147/DMSO.S61438
7.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047.
[PubMed]
https://doi.org/10.1001/jama.298.17.2038
8.
Fourtounas C: Transplant options for patients with type 2 diabetes and chronic kidney disease. World J Transplant 2014; 4: 102–110.
[PubMed]
https://doi.org/10.5500/wjt.v4.i2.102
9.
Bonnin S, Sandali O, Bonnel S, Monin C, El Sanharawi M: Vitrectomy with internal limiting membrane peeling for tractional and nontractional diabetic macular edema: long-term results of a comparative study. Retina 2015; 35: 921–928.
[PubMed]
https://doi.org/10.1097/IAE.0000000000000433
10.
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915–923.
[PubMed]
https://doi.org/10.1097/IAE.0b013e318206d18c
11.
Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al: Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 2010; 304: 649–656.
[PubMed]
https://doi.org/10.1001/jama.2010.1111
12.
Romero-Aroca P: Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes 2011; 2: 98–104.
[PubMed]
https://doi.org/10.4239/wjd.v2.i6.98
13.
Ding J, Wong TY: Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012; 12: 346–354.
[PubMed]
https://doi.org/10.1007/s11892-012-0283-6
14.
Leveziel N, Ragot S, Gand E, Lichtwitz O, Halimi JM, Gozlan J, et al: Association between diabetic macular edema and cardiovascular events in type 2 diabetes patients: a multicenter observational study. Medicine (Baltimore) 2015; 94:e1220.
[PubMed]
https://doi.org/10.1097/MD.0000000000001220
15.
Ascaso FJ, Huerva V, Grzybowski A: The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm 2014; 2014: 432685.
[PubMed]
https://doi.org/10.1155/2014/432685
16.
Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98–107.
[PubMed]
https://doi.org/10.1038/nri2925
17.
Tang J, Kern TS: Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011; 30: 343–358.
[PubMed]
https://doi.org/10.1016/j.preteyeres.2011.05.002
18.
Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986; 77: 908–915.
[PubMed]
https://doi.org/10.1172/JCI112389
19.
Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020–1024.
[PubMed]
https://doi.org/10.2337/diab.37.8.1020
20.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599–622.
[PubMed]
https://doi.org/10.1210/er.2001-0039
21.
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517–1526.
[PubMed]
https://doi.org/10.1056/NEJMoa065213
22.
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673–1677.
[PubMed]
https://doi.org/10.1126/science.1061620
23.
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R: Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273.
[PubMed]
https://doi.org/10.1155/2016/2156273
24.
Abcouwer SF: Angiogenic factors and cytokines in diabetic retinopathy. J Clin Cell Immunol 2013;suppl 1: 1–12.
[PubMed]
https://doi.org/10.4172/2155-9899
25.
Adamis AP, Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30: 65–84.
[PubMed]
https://doi.org/10.1007/s00281-008-0111-x
26.
Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, et al: Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 2009; 175: 2676–2685.
[PubMed]
https://doi.org/10.2353/ajpath.2009.080945
27.
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450–1452.
[PubMed]
https://doi.org/10.1096/fj.03-1476fje
28.
Joussen AM, Smyth N, Niessen C: Pathophysiology of diabetic macular edema; in Lang GE (ed): Developments in Ophthalmology. Basel, Karger, 2007, pp 1–12.
29.
Li J, Wang JJ, Yu Q, Wang M, Zhang SX: Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. FEBS Lett 2009; 583: 1521–1527.
[PubMed]
https://doi.org/10.1016/j.febslet.2009.04.007
30.
Zhang X, Zeng H, Bao S, Wang N, Gillies MC: Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014; 4: 27.
[PubMed]
https://doi.org/10.1186/2045-3701-4-27
31.
Zhu T, Ma J, Li Y, Zhang Z: Association between retinal neuronal degeneration and visual function impairment in type 2 diabetic patients without diabetic retinopathy. Sci China Life Sci 2015; 58: 550–555.
[PubMed]
https://doi.org/10.1007/s11427-015-4858-8
32.
Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C: Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015; 2015: 582060.
[PubMed]
https://doi.org/10.1155/2015/582060
33.
Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, et al: Pro-permeability factors in diabetic macular edema; the Diabetic Macular Edema Treated With Ozurdex Trial. Am J Ophthalmol 2016; 168: 13–23.
[PubMed]
https://doi.org/10.1016/j.ajo.2016.04.017
34.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al: Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237: 185–222.
[PubMed]
https://doi.org/10.1159/000458539
35.
Park YG, Kim EY, Roh YJ: Laser-based strategies to treat diabetic macular edema: history and new promising therapies. J Ophthalmol 2014; 2014: 769213.
[PubMed]
https://doi.org/10.1155/2014/769213
36.
Shamsi HN, Masaud JS, Ghazi NG: Diabetic macular edema: new promising therapies. World J Diabetes 2013; 4: 324–338.
[PubMed]
https://doi.org/10.4239/wjd.v4.i6.324
37.
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609–614.
[PubMed]
https://doi.org/10.1016/j.ophtha.2010.12.033
38.
Diabetic Retinopathy Clinical Research Network: Aflibercept, bevacizumab, or ranibiz­umab for diabetic macular edema. N Engl J Med 2015; 372: 1193–1203.
[PubMed]
https://doi.org/10.1056/NEJMoa1414264
39.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123: 1351–1359.
[PubMed]
https://doi.org/10.1016/j.ophtha.2016.02.022
40.
Hadayer A, Schaal S: Delivery of steroids into the eye for the treatment of macular edema. Expert Opin Drug Deliv 2016; 13: 1083–1091.
[PubMed]
https://doi.org/10.1080/17425247.2016.1182488
41.
Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al: Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013; 58: 291–310.
[PubMed]
https://doi.org/10.1016/j.survophthal.2012.08.003
42.
Sociedad Española de Retina y Vítreo: Manejo de las complicaciones oculares de la diabetes. Retinopatía Diabética y Edema Macular. Guías de Práctica Clínica de la SERV. Segunda Revisión 2015. www.serv.es (accessed October 2015).
43.
Sarao V, Veritti D, Boscia F, Lanzetta P: Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014; 2014: 989501.
[PubMed]
https://doi.org/10.1155/2014/989501
44.
Wang K, Wang Y, Gao L, Li X, Li M, Guo J: Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31: 1541–1546.
[PubMed]
https://doi.org/10.1248/bpb.31.1541
45.
Reichenbach A, Wurm A, Pannicke T, Ian­diev I, Wiedemann P, Bringmann A: Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 627–636.
[PubMed]
https://doi.org/10.1007/s00417-006-0516-y
46.
Chung H, Hwang JJ, Koh JY, Kim J, Yoon YH: Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest Ophthalmol Vis Sci 2007; 48: 5742–5749.
[PubMed]
https://doi.org/10.1167/iovs.07-0566
47.
Smit-McBride Z, Modjtahedi SP, Morse LS: Dexamethasone’s uses in retinal diseases. 2013. https://ucdavis.pure.elsevier.com/en/publications/dexamethasones-uses-in-retinal-diseases (accessed September 20, 2017).
48.
Grover DA, Li T, Chong CC: Intravitreal steroids for macular edema in diabetes. Coch­rane Database Syst Rev 2008; 1:CD005656.
[PubMed]
https://doi.org/10.1002/14651858.CD005656.pub2
49.
Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology 2011; 118: 2453–2460.
[PubMed]
https://doi.org/10.1016/j.ophtha.2011.05.014
50.
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545–553.
[PubMed]
https://doi.org/10.1001/archophthalmol.2010.339
51.
Ferris FL, Kassoff A, Bresnick GH, Bailey I: New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91–96.
[PubMed]
52.
Maturi RK, Pollack A, Uy HS, Varano M, Gomes AMV, Li XY, et al: Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 2016; 36: 1143–1152.
[PubMed]
https://doi.org/10.1097/IAE.0000000000001004
53.
Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M: Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica 2015; 233: 176–185.
[PubMed]
https://doi.org/10.1159/000371770
54.
Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al: Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study (in French). J Fr Ophtalmol 2014; 37: 480–485.
[PubMed]
https://doi.org/10.1016/j.jfo.2014.03.001
55.
Matonti F, Pommier S, Meyer F, Hajjar C, Merite PY, Parrat E, et al: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 2016; 26: 454–459.
[PubMed]
https://doi.org/10.5301/ejo.5000787
56.
Malclès A, Dot C, Voirin N, Agard É, Vié AL, Bellocq D, et al: Real-life study in diabetic macular edema treated with dexamethasone implant: the RELDEX study. Retina 2017; 37: 753–760.
[PubMed]
https://doi.org/10.1097/IAE.0000000000001234
57.
Aknin I, Melki L: Longitudinal study of sustained-release dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmologica 2016; 235: 187–188.
[PubMed]
https://doi.org/10.1159/000446194
58.
Pacella F, Romano MR, Turchetti P, Tarquini G, Carnovale A, Mollicone A, et al: An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 2016; 9: 1427–1432.
[PubMed]
https://doi.org/10.18240/ijo.2016.10.10
59.
Dutra Medeiros M, Alkabes M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B: Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther 2014; 30: 709–716.
[PubMed]
https://doi.org/10.1089/jop.2014.0010
60.
Pelegrín L, de la Maza MS, Molins B, Ríos J, Adán A: Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye 2015; 29: 943–950.
[PubMed]
https://doi.org/10.1038/eye.2015.73
61.
Fassbender Adeniran JM, Jusufbegovic D, Schaal S: Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm 2017; 25: 834–840.
[PubMed]
https://doi.org/10.1080/09273948.2016.1184284
62.
Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al: Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117: 1087–1093.e3.
[PubMed]
https://doi.org/10.1016/j.ophtha.2009.10.040
63.
Jusufbegovic D, Schaal S: Quiescent herpes simplex keratitis reactivation after intravitreal injection of dexamethasone implant. Retin Cases Brief Rep 2017; 11: 296–297.
[PubMed]
https://doi.org/10.1097/ICB.0000000000000376
64.
Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al: A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121: 2473–2481.
[PubMed]
https://doi.org/10.1016/j.ophtha.2014.07.002
65.
Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al: Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology 2016; 123: 1399–1401.
[PubMed]
https://doi.org/10.1016/j.ophtha.2015.12.012
66.
Pacella E, Torre GL, Turchetti P, Merisola C, Lenzi T, Mazzeo F, et al: Evaluation of efficacy dexamethasone intravitreal implant compared to treatment with anti-VEGF in the treatment of diabetic macular edema. Senses Sci 2014; 1: 164–168.
67.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology 2013; 120: 2013–2022.
[PubMed]
https://doi.org/10.1016/j.ophtha.2013.02.034
68.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al: Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2016; 123: 2376–2385.
[PubMed]
https://doi.org/10.1016/j.ophtha.2016.07.032
69.
Călugăru D, Călugăru M: Pro-permeability factors in diabetic macular edema; the Diabetic Macular Edema Treated With Ozurdex Trial. Am J Ophthalmol 2016; 170: 244–245.
[PubMed]
https://doi.org/10.1016/j.ajo.2016.06.048
70.
Matonti F, Guigou S, Pommier S, Meyer F, Hajjar C, Merite PY, et al: Dexamethasone implants in patients with naive diabetic macular edema. Ophthalmologica 2016; 235: 244.
[PubMed]
https://doi.org/10.1159/000446296
71.
Ito S, Miyamoto N, Ishida K, Kurimoto Y: Association between external limiting membrane status and visual acuity in diabetic macular oedema. Br J Ophthalmol 2013; 97: 228–232.
[PubMed]
https://doi.org/10.1136/bjophthalmol-2011-301418
72.
Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al: Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 2014; 132: 1309–1316.
[PubMed]
https://doi.org/10.1001/jamaophthalmol.2014.2350
73.
Iacono P, Parodi MB, Scaramuzzi M, Bandello F: Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol 2017; 101: 791–795.
[PubMed]
https://doi.org/10.1136/bjophthalmol-2016-308726
74.
Navarrete-Sanchis J, Zarco-Bosquets J, Tomas-Torrent JM, Diago T, Ortega-Evangelio L: Long-term effectiveness of vitrectomy in diabetic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2015; 253: 713–719.
[PubMed]
https://doi.org/10.1007/s00417-014-2745-9
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.